AU6279598A - Biazacyclic CRF antagonists - Google Patents

Biazacyclic CRF antagonists

Info

Publication number
AU6279598A
AU6279598A AU62795/98A AU6279598A AU6279598A AU 6279598 A AU6279598 A AU 6279598A AU 62795/98 A AU62795/98 A AU 62795/98A AU 6279598 A AU6279598 A AU 6279598A AU 6279598 A AU6279598 A AU 6279598A
Authority
AU
Australia
Prior art keywords
alkyl
amino
mono
βalkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62795/98A
Other languages
English (en)
Inventor
James R. Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of AU6279598A publication Critical patent/AU6279598A/en
Priority to AU85551/01A priority Critical patent/AU769402B2/en
Priority to AU2004201701A priority patent/AU2004201701A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU62795/98A 1997-02-18 1998-02-17 Biazacyclic CRF antagonists Abandoned AU6279598A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU85551/01A AU769402B2 (en) 1997-02-18 2001-10-31 Biazacyclic CRF antagonists
AU2004201701A AU2004201701A1 (en) 1997-02-18 2004-04-22 Biazacyclic CRF antagonists

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US3641597P 1997-02-18 1997-02-18
US3642197P 1997-02-18 1997-02-18
US3641497P 1997-02-18 1997-02-18
US3642297P 1997-02-18 1997-02-18
US3641697P 1997-02-18 1997-02-18
US3642397P 1997-02-18 1997-02-18
US60036422 1997-02-18
US60036421 1997-02-18
US60036414 1997-02-18
US60036416 1997-02-18
US60036415 1997-02-18
US60036423 1997-02-18
PCT/US1998/002932 WO1998035967A2 (en) 1997-02-18 1998-02-17 Biazacyclic crf antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU85551/01A Division AU769402B2 (en) 1997-02-18 2001-10-31 Biazacyclic CRF antagonists

Publications (1)

Publication Number Publication Date
AU6279598A true AU6279598A (en) 1998-09-08

Family

ID=27556309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62795/98A Abandoned AU6279598A (en) 1997-02-18 1998-02-17 Biazacyclic CRF antagonists

Country Status (6)

Country Link
US (2) US6352990B1 (enExample)
EP (1) EP0970082A2 (enExample)
JP (1) JP2001511813A (enExample)
AU (1) AU6279598A (enExample)
CA (1) CA2281525A1 (enExample)
WO (1) WO1998035967A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622386D0 (en) * 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
CA2281525A1 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
AU746706B2 (en) 1997-07-03 2002-05-02 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6271380B1 (en) * 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
ATE318267T1 (de) * 1999-09-30 2006-03-15 Neurogen Corp Einige alkylendiamin-substituierte heterocyclen
US7045529B2 (en) 1999-12-17 2006-05-16 Bristol-Myers Squibb Company Imidazopyrimidinyl and imidazopyri dinyl derivatives
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
PL368555A1 (en) 2001-01-26 2005-04-04 Bristol-Myers Squibb Company Imidazolyl derivatives as corticotropin releasing factor inhibitors
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
WO2002076984A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
CZ301491B6 (cs) 2001-04-27 2010-03-24 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a]pyridiny a léciva s jejich obsahem
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1555265B1 (en) * 2002-10-22 2009-03-25 Eisai R&D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
US7034023B2 (en) * 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
US7557111B2 (en) 2004-01-06 2009-07-07 Taisho Pharmaceutical Co., Ltd. Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
WO2005066142A2 (en) * 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists
PT1732933E (pt) * 2004-03-26 2008-10-20 Lilly Co Eli Compostos para o tratamento da dislipidémia
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
DE102005007160A1 (de) * 2005-02-16 2006-08-24 Basf Ag Pyrazolcarbonsäureanilide, Verfahren zu ihrer Herstellung und sie enthaltende Mittel zur Bekämpfung von Schadpilzen
AU2006261607A1 (en) * 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C.
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US8637531B2 (en) * 2006-12-26 2014-01-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyridmidines useful for treating viral infections
US8143394B2 (en) * 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
NZ588376A (en) 2008-04-15 2011-06-30 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
US20110152313A1 (en) * 2008-06-20 2011-06-23 Macquarie University Synthesis of ageladine a and analogs thereof
US8536187B2 (en) * 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
NZ601483A (en) 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102796133B (zh) * 2011-05-27 2015-05-20 北京大学 一种稀土铕配合物及其作为发光材料的应用
ES2575092T3 (es) 2011-06-27 2016-06-24 Janssen Pharmaceutica, N.V. Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina
WO2013033068A1 (en) * 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PT2750677T (pt) 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
MX377235B (es) * 2013-07-23 2025-03-07 Bayer Cropscience Ag Proceso mejorado para preparar bifenilanilidas y bifenilanilinas cloradas.
JP2017520610A (ja) 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション，インコーポレーテッド Ｈｉｖ関連障害を治療するための方法及び組成物
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
WO2019002132A1 (en) 2017-06-30 2019-01-03 Bayer Animal Health Gmbh NEW AZAQUINOLINE DERIVATIVES
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法
MX2021005314A (es) * 2018-11-09 2021-08-24 Vivace Therapeutics Inc Compuestos biciclicos.
US12497365B2 (en) 2019-01-14 2025-12-16 Qingdao Kingagroot Chemical Compound Co., Ltd. 4-pyridinyl formamide compound or derivative thereof, preparation method therefor, herbicidal composition and use thereof
KR20220016456A (ko) 2019-04-16 2022-02-09 비바체 테라퓨틱스, 인크. 바이사이클릭 화합물
WO2025032038A1 (en) 2023-08-09 2025-02-13 Bayer Aktiengesellschaft Pyridazin-4-yloxadiazines as novel fungicides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
CN1056611C (zh) * 1994-06-16 2000-09-20 美国辉瑞有限公司 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
DE69603240T2 (de) * 1995-05-12 2000-01-05 Neurogen Corp., Branford Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
PT778277E (pt) * 1995-12-08 2003-11-28 Pfizer Derivados heterociclicos substituidos como antagonistas do crf
DE69736513T2 (de) * 1996-02-07 2007-04-05 Neurocrine Biosciences, Inc., San Diego Pyrazolopyrimidine als crf rezeptor-antagonisten
US6022978A (en) * 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
HU228962B1 (en) * 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo triazines, pharmaceutical compositions containing them and use of the compounds
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
ES2273369T3 (es) * 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
CA2281525A1 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists

Also Published As

Publication number Publication date
US20020049207A1 (en) 2002-04-25
US6352990B1 (en) 2002-03-05
WO1998035967A2 (en) 1998-08-20
WO1998035967A3 (en) 1998-12-10
US6974808B2 (en) 2005-12-13
CA2281525A1 (en) 1998-08-20
JP2001511813A (ja) 2001-08-14
EP0970082A2 (en) 2000-01-12

Similar Documents

Publication Publication Date Title
US6352990B1 (en) CRF receptor antagonists and methods relating thereto
NZ330119A (en) Pyrazolopyrimidines as crf receptor antagonists
US6531475B1 (en) CRF receptor antagonists and methods relating thereto
EP1129091B1 (en) Crf receptor antagonists and methods relating thereto
WO2000027850A2 (en) Crf receptor antagonists and methods relating thereto
EP1697374B1 (en) Crf receptor antagonists and methods relating thereto
AU2002239589B2 (en) CRF receptor antagonists and methods relating thereto
AU2002239589A1 (en) CRF receptor antagonists and methods relating thereto
US7446108B2 (en) Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists
US6440960B1 (en) CRF receptor antagonists and methods relating thereto
US6613777B1 (en) CRF antagonistic pyrazolo[4,3-b]pyridines
EP1282624B1 (en) Crf receptor antagonists and methods relating thereto
AU769402B2 (en) Biazacyclic CRF antagonists

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: AMEND THE TITLE OF THE INVENTION TO READ BIAZACYCLIC CRF ANTAGONISTS.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted